Showing results (1311-1320 of 1,423) with videos related to
Sort By:
Pageof 143
JACC. Advances|April 23, 2026
The Clinical Impact of Patent Foramen Ovale in Patients With Carcinoid Heart DiseaseIsabel G Scalia, Omar H Ibrahim, Fatmaelzahraa E Abdelfattah, et al.Future Oncology (London, England)|October 6, 2025
EA1211: interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy (DIRECT trial)Maeve A Hennessy, Constantine Gatsonis, Heather Jacene, et al.Breast Cancer Research and Treatment|May 13, 2018
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trialCesar A Santa-Maria, Aditya Bardia, Amanda L Blackford, et al.Plos One|October 19, 2020
Medical management of muscle weakness in Duchenne muscular dystrophySarah R Rivera, Sumit K Jhamb, Hoda Z Abdel-Hamid, et al.Epilepsia|October 3, 2001
Surgical resection for intractable epilepsy in "double cortex" syndrome yields inadequate resultsA Bernasconi, V Martinez, P Rosa-Neto, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 8, 2017
In Vivo Imaging of the Programmed Death Ligand 1 by <sup>18</sup>F PETDinko E González Trotter, Xiangjun Meng, Paul McQuade, et al.Journal of Neuroendocrinology|June 30, 2026
Outcomes of liver resections for neuroendocrine tumor liver metastases in carcinoid heart diseaseMarkus Ammann, Hallbera Gudmundsdottir, Vanja Podrascanin, et al.Neuromuscular Disorders : NMD|December 24, 2023
Continued safety and long-term effectiveness of onasemnogene abeparvovec in OhioMegan A Waldrop, Shannon Chagat, Michael Storey, et al.Nature Medicine|September 13, 2024
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trialNadia Harbeck, Eva Ciruelos, Guy Jerusalem, et al.JHLT Open|February 2, 2026
Bronchial stenosis after lung transplant: Risk factors and clinical outcomesAntonio Coppolino, Rie Maurer, Ella Woehl, et al.Pageof 143